Skip to content

CoMotion In the News

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

This CoMotion In The News article is from the Takeda website. Please click the button below to go to the site.